Lenalidomide and Zovia 1/35e

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using lenalidomide together with ethinyl estradiol may increase the risk of dangerous blood clots. The risk is higher if you are using lenalidomide with dexamethasone for the treatment of multiple myeloma than if you are using lenalidomide alone for some other condition. You should seek immediate medical attention if you experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, difficulty breathing, coughing up blood, sudden loss of vision, and/or pain, redness or swelling in an arm or leg. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use of lenalidomide. Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been observed at significantly increased rates when lenalidomide was coadministered with dexamethasone for the treatment of multiple myeloma. In two clinical trials consisting of a total of 703 multiple myeloma patients, DVT was reported as a serious or Grade 3/4 adverse drug reaction in 7.4% and 8.2% of patients in the lenalidomide/dexamethasone group (n=353), respectively, compared to 3.1% and 3.4% of patients in the placebo/dexamethasone group (n=350), respectively. Likewise, PE was reported as a serious or Grade 3/4 adverse drug reaction in 3.7% of patients in the lenalidomide/dexamethasone group versus 0.9% of patients in the placebo/dexamethasone group. Venous thromboembolic events have also been reported during lenalidomide monotherapy for the treatment of myelodysplastic syndromes.

MANAGEMENT: The use of estrogen-containing medications including combined oral contraceptive pills should be undertaken with caution in patients receiving lenalidomide, particularly multiple myeloma patients receiving lenalidomide with dexamethasone. Patients should be apprised of the increased risk of venous thromboembolic events if a combined oral contraceptive pill is chosen as one of two effective methods of contraception that must be used simultaneously and continuously for 4 weeks before, during (even in case of dose interruption), and for 4 weeks after lenalidomide therapy. Input from a gynecologist or similar expert on adequate contraception should be sought as needed. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs. It is not known whether prophylactic anticoagulation or antiplatelet therapy may lessen the risk of venous thromboembolic events. The decision to take prophylactic measures should be done carefully after an assessment of underlying risk factors. If a thromboembolic event occurs during therapy with lenalidomide, treatment must be discontinued and standard anticoagulation therapy started. Once anticoagulation is stabilized and complications of the thromboembolic event under control, lenalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks. Anticoagulation therapy should be continued during the remaining course of lenalidomide treatment.

Lenalidomide

Generic Name: lenalidomide

Brand name: Revlimid

Synonyms: n.a.

What is Lenalidomide?

Zovia 1/35e

Generic Name: ethinyl estradiol / ethynodiol

Brand name: Kelnor, Zovia 1/35, Zovia 1/50, Demulen 1/35, Demulen 1/50, Zovia 1/35e, Kelnor 1/50, Kelnor 1/35, Zovia 1/50e

Synonyms: Zovia 1/35, Zovia 1/35E

What is Zovia 1/35e?